Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets
September 22, 2011
Wellesley, Mass. – In a recent release, SAMPLE PREPARATION IN GENOMICS, PROTEOMICS, AND EPIGENOMICS: GLOBAL MARKETS (BIO089A) from BCC Research (www.bccresearch.com), the global market for sample preparation products and reagents totaled nearly $3.6 billion in 2011, and is expected to hold a value of nearly $8.5 billion in 2016, increasing at a five-year compound annual growth rate (CAGR) of 18.8%.
The global market for sample preparation products and reagents can be broken down by three segments – genomics, epigenomics, and proteomics.
The genomics segment held a value of more than $1.9 billion in 2011, and is expected to increase at a CAGR of 16.1% to reach $4.1 billion in 2016.
The epigenomics segment held a value of $1.4 billion in 2011, and is expected to increase at a CAGR of 22.7 % to reach $3.9 billion in 2016.
The proteomics segment was worth $220 million in 2011 and should be worth $450 billion in 2016, a CAGR of 15.4%.
Every scientific achievement is based on reliable and reproducible experimental design. For many scientists, protocols and technical procedures play a key role in their discoveries. Therefore, sample preparation techniques are the necessary and essential step in many successful studies requiring, in most cases, specific approaches, reagents, and design.
Reagents companies started to recognize commercial potential in providing the required reagents, kits, and assays that help to facilitate this scientific work by reducing time, labor, and even costs. Slowly, sample preparation products are evolving into a specific market space with their own trends, influences, and challenges.
Today, many companies realize that efficient experimental procedure is a key to achieving a fast and successful drug discovery process. Consequently, life-science tools and sample preparation procedures are continuing to gain more attention. Sample prep products are part of the life-science-tools industry and provide not only kits or consumables but also equipment and services.
This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment of the market for sample preparation in genomics, proteomics, and epigenomics research. The report provides insights into the market positions of major companies, and shows new opportunities otherwise overlooked or less known to the business community.
Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets( BIO089A )
Publish Date: Sep 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum